The Extracellular Domain of Two-component System Sensor Kinase VanS from Streptomyces coelicolor Binds Vancomycin at a Newly Identified Binding Site

Christine Lockey1, Richard J. Edwards2, David I. Roper3 & Ann M. Dixon4*

The glycopeptide antibiotic vancomycin has been widely used to treat infections of Gram-positive bacteria including Clostridium difficile and methicillin-resistant Staphylococcus aureus. However, since its introduction, high level vancomycin resistance has emerged. The genes responsible require the action of the two-component regulatory system VanSR to induce expression of resistance genes. The mechanism of detection of vancomycin by this two-component system has yet to be elucidated. Diverging evidence in the literature supports activation models in which the VanS protein binds either vancomycin, or Lipid II, to induce resistance. Here we investigated the interaction between vancomycin and VanS from Streptomyces coelicolor (VanSSc), a model Actinomycete. We demonstrate a direct interaction between vancomycin and purified VanSSc and traced these interactions to the extracellular region of the protein, which we reveal adopts a predominantly α-helical conformation. The VanSSc-binding epitope within vancomycin was mapped to the N-terminus of the peptide chain, distinct from the binding site for Lipid II. In targeting a separate site on vancomycin, the effective VanS ligand concentration includes both free and lipid-bound molecules, facilitating VanS activation. This is the first molecular description of the VanS binding site within vancomycin, and could direct engineering of future therapeutics.

Vancomycin is a glycopeptide antibiotic that exerts its antimicrobial effect on a variety of Gram-positive bacterial species, and has been seen as a last line of defence in the treatment of complicated clinical infections including Clostridium difficile and methicillin-resistant Staphylococcus aureus (MRSA). Despite the significant toxicity of vancomycin in patients, there is still strong clinical reliance on this drug as a last line of defence against such infections1. In some cases, MRSA infections are incalcitrant and vancomycin-resistant Enterococcal (VRE) strains are resistant to a wide panel of antibiotics. As a result, VRE and MRSA strains are now on worldwide health authorities' high priority lists, and new treatments are desperately needed1-9. Three recently approved semi-synthetic glycopeptide derivatives, oritavancin, dalbavancin and telavancin, are being treated as reserve antibiotics to be used sparingly to preserve their efficacy4.

The mode of action of vancomycin involves binding to the d-alanyl-d-alanine-terminating pentapeptide of the cell wall precursor Lipid II, preventing its utilisation in biosynthesis of bacterial peptidoglycan cell wall6. Vancomycin is one of a number of antibiotics that target Lipid II rather than the enzymes that use Lipid II as a substrate9. Inducible high-level resistance to vancomycin is commonly found in soil bacteria including the Actinomycetes where it has been genome-encoded for millennia9. Recently resistance genes have spread intergenerically into S. aureus, resulting in the first strains of vancomycin- and methicillin-resistant S. aureus (VRSA) causing widespread clinical concern9. High-level vancomycin resistance is induced through the upregulation of genes in the transposon-encoded van gene cluster and was first characterised in a VRE isolate9,10-12. These genes

1MOAC Doctoral Training Centre, University of Warwick, Coventry, CV4 7AL, UK. 2Medical Research Council Doctoral Training Centre, University of Warwick, Coventry, CV4 7AL, UK. 3School of Life Sciences, University of Warwick, Coventry, CV4 7AL, UK. 4Department of Chemistry, University of Warwick, Coventry, CV4 7AL, UK. *email: ann.dixon@warwick.ac.uk
encode a series of enzymes that coordinate to break down the cell’s supply of d-alanyl-d-alanine for peptidoglycan biosynthesis, and replace it with d-alanyl-d-lactate. The resulting d-alanyl-d-lactate-containing Lipid II is then integrated into the cell wall by existing cellular machinery; the affinity of this modified precursor for vancomycin is reduced approximately 1000-fold, and vancomycin is therefore unable to disrupt the synthesis of the bacterial cell wall peptidoglycan, resulting in vancomycin-resistant cell growth.

The upregulation of genes in the van cluster is controlled by the VanSR two-component regulatory system. VanS is an integral membrane protein and sensor histidine kinase, with a domain architecture and predicted topology as shown in Figure 1B-C. VanS is essential for the detection and response to the presence of vancomycin in the cellular environment. In the presence of such a stimulus, VanS is thought to dimerise, undergo autophosphorylation in its cytoplasmic kinase domain, and then transfer the acquired phosphate group to VanR, the cytosolic response regulator. Phosphorylated VanR binds upstream of the van transcription elements, and induces expression of these proteins.

While the role of VanS in inducing vancomycin resistance is well characterised and understood, the exact mechanism by which VanS initially detects vancomycin in the cellular environment remains the subject of debate. Evidence in the literature supports different models in which VanS is activated by direct binding of vancomycin, or by accumulation of uncrosslinked Lipid II, a by-product of vancomycin activity. A thorough characterisation of the VanS activation mechanism is required to understand this biological mechanism and may provide the knowledge base to resensitise vancomycin-resistant bacteria to continued use of this vital antibiotic.

Streptomyces coelicolor is a model Actinomycete species which displays inducible vancomycin resistance of the VanB phenotype. The VanB phenotype is one of six recognised resistance phenotypes of vancomycin-resistant bacteria, all of which involve the alteration of Lipid II. VanA and VanB strains are highly resistant to vancomycin making them the most clinically relevant phenotypes, and have a highly similar domain architecture, but are differentiated from one another by their resistance to the antibiotic Teicoplanin: VanA strains are resistant to Teicoplanin; VanB strains are sensitive. The VanS protein in S. Coelicolor, VanSSC, is a 42 kDa integral membrane protein and the subject of the work presented here. This protein is of particular interest following the report by Koteva and co-workers that it acts as a vancomycin receptor. Specifically, it was suggested that a putative vancomycin-binding site is located at the N-terminus between residues 1–41, which includes the putative first transmembrane helix and residues D38–W41 of the sensor loop. However, to our knowledge, no further refinement of this location nor any molecular model of this interaction site has been proposed since, and there is no X-ray or NMR structure of the protein available. We wished to define the molecular determinants for vancomycin recognition in this system, both from within vancomycin itself as well as within VanS.

In this report, we demonstrate the direct interaction between vancomycin and purified VanSSC using a range of biochemical and biophysical methods including solution state nuclear magnetic resonance (NMR) spectroscopy.
We have studied both the full-length VanSSC protein and a synthetic peptide corresponding to its extracellular domain in order to trace these interactions to the extracellular “sensor” region of the protein, a region that we also show has a highly α-helical secondary structure. Utilising the protons in vancomycin as chemical probes of interaction, we have used NMR to map the VanS binding site within vancomycin to a region at the N-terminus of the peptide chain that is almost entirely distinct from the lipid II binding site through which vancomycin’s anti-microbial activity is achieved. To our knowledge, this is the first molecular description of the VanS binding site within vancomycin, and could direct design of new therapeutics or modification of current antibiotics.

RESULTS

Purified full-length VanSSC is well-folded, dimeric and active in detergent micelles. Full-length VanSSC from S. coelicolor, containing an N-terminal His6 tag, was expressed in E. coli and purified as detailed in the Methods. Solubilisation of the protein in the zwitterionic detergent dodecylphosphocholine (DPC) and the lysolipid 1-myristoyl-2-hydroxy-sn-glycero-3-phospho-(1′-rac-glycerol) (LMPG), both detergents with an excellent track record of solubilising membrane proteins for structural studies26–29, yielded highly similar CD spectra that suggested high α-helical content from the negative peaks at 208 and 222 nm (Fig. 2A). The maximum helical content was calculated from mean residue ellipticity at 222 nm30 to be approximately 32%. In the absence of a three-dimensional structure for VanSSC, the Sequence Annotated by Structure (SAS) tool of EMBL-EBI31 was used to predict the percentage helicity of VanSSC from its amino acid sequence. The tool estimated that VanSSC is 36% α-helical, in good agreement with our results, suggesting that the protein is similarly well-folded in DPC and LMPG micelles.

We have studied both the full-length VanSSC protein and a synthetic peptide corresponding to its extracellular domain in order to trace these interactions to the extracellular “sensor” region of the protein, a region that we also show has a highly α-helical secondary structure. Utilising the protons in vancomycin as chemical probes of interaction, we have used NMR to map the VanS binding site within vancomycin to a region at the N-terminus of the peptide chain that is almost entirely distinct from the lipid II binding site through which vancomycin’s anti-microbial activity is achieved. To our knowledge, this is the first molecular description of the VanS binding site within vancomycin, and could direct design of new therapeutics or modification of current antibiotics.

RESULTS

Purified full-length VanSSC is well-folded, dimeric and active in detergent micelles. Full-length VanSSC from S. coelicolor, containing an N-terminal His6 tag, was expressed in E. coli and purified as detailed in the Methods. Solubilisation of the protein in the zwitterionic detergent dodecylphosphocholine (DPC) and the lysolipid 1-myristoyl-2-hydroxy-sn-glycero-3-phospho-(1′-rac-glycerol) (LMPG), both detergents with an excellent track record of solubilising membrane proteins for structural studies26–29, yielded highly similar CD spectra that suggested high α-helical content from the negative peaks at 208 and 222 nm (Fig. 2A). The maximum helical content was calculated from mean residue ellipticity at 222 nm30 to be approximately 32%. In the absence of a three-dimensional structure for VanSSC, the Sequence Annotated by Structure (SAS) tool of EMBL-EBI31 was used to predict the percentage helicity of VanSSC from its amino acid sequence. The tool estimated that VanSSC is 36% α-helical, in good agreement with our results, suggesting that the protein is similarly well-folded in DPC and LMPG micelles.
A further test of how effectively micelles preserve the fold of VanSC is the retention of the native oligomeric state of the protein. Although the oligomeric state of VanSC has yet to be reported, sequence analysis indicates the presence of a HAMP domain, implicated in signalling of specifically dimeric sensor kinases. We investigated the oligomeric state of DPC-solubilised VanSC using gel filtration chromatography (GFC) and blue native PAGE (BN-PAGE). Apart from protein aggregates (≥ 300 kDa) which eluted in the void volume (Ve) of 9.0 mL, VanSC was analysed by GFC eluted in a single peak centred at an elution volume (Ve) of 11.5 mL (Fig. 2B). Comparison of the Ve to those obtained from gel filtration standards (Fig. 2B inset right) and S2 suggests that the primary species for VanSC in DPC is that of a dimer (~80–90 kDa, monomeric molecular weight = 42.6 kDa), reflecting the predicted native oligomeric state of this protein. This propensity to oligomerise was also observed by BN-PAGE, which provides a measure of molecular size relative to standards in non-denaturing conditions. DPC supported formation of discrete VanSC oligomers (Fig. 2B inset left, lanes 2 and 3). We interpret the weak band just below 66 kDa as monomeric VanSC, and note that although this is ~50% above the theoretical mass of the protein, proteins with pI values ≥ 9.3 typically display slow migration in BN-PAGE reflecting inaccurately high molecular mass. In a standard SDS-PAGE analysis, our purified protein migrated in accordance with its theoretical mass. Although the helical content and dimer formation mirrored the in vitro properties of VanS, the ability of this protein to function as a kinase or phosphatase may be affected when solubilised in detergents. Previous studies have shown that the addition of detergent can hamper autophosphorylation and dephosphorylation rate of histidine kinases. Therefore, it was critical to assess the activity of purified VanSSC in protein to function as a kinase or phosphatase may be affected when solubilised in detergents. Previous studies maintained in detergent micelles and the protein was suitable for further biophysical study. The magnitude of the change in BODIPY emission under the conditions used here was first evaluated using Lipid II, which is known to bind strongly to vancomycin with a binding constant of 54 μM⁻¹. Titration of Lipid II into DPC-solubilised BODIPY-vancomycin yielded a red shift in λem of 4.5 nm (Fig. 4B), indicating that Lipid II and BODIPY-vancomycin interact as expected. This interaction was nearly saturated at the lowest Lipid II concentration studied (0.1 μM), with successive additions of Lipid II having little impact on λem. This reﬂects the reported 1:1 stoichiometry of Lipid II:Vancomycin binding. This approach was then applied to study of BODIPY-vancomycin interactions with VanSC. Addition of 1 μM VanSC yielded a red shift in λem of 2 nm (Fig. 4B), and further aliquots of VanSC were added until no appreciable change in the spectrum was observed. Emission spectra of the BODIPY dye did not display the same level of quenching in these experiments, but a cumulative red shift in λem of 3 nm was observed, which is similar to that of the Lipid II positive control, and suggests that full-length VanSC interacts directly with the vancomycin analogue. To conﬁrm the speciﬁcity of this interaction, the experiment was repeated substituting bovine serum albumin (BSA) as a putative binding partner for BODIPY-vancomycin, given that BSA has a large number of readily accessible α-helices. Addition of BSA from 1 μM to 5 μM yielded no shift in λem of BODIPY-vancomycin (Fig. 4A, inset), indicating that the red shift observed in the presence of VanSC represents a selective interaction between VanSC and the antibiotic.
VanSSC sensor-loop region forms an α-helix in the presence of a membrane mimetic and experiences significant change in dynamics upon addition of vancomycin. The fluorescence results above lead to the obvious question of where the vancomycin-binding site was located within our purified VanSSC. Full-length VanSSC was subjected to two- and three-dimensional heteronuclear NMR analyses but produced broad NMR signals (data not shown) due to the slow tumbling of the detergent-solubilised dimer in solution (analogous to a >100 kDa protein). As a result we focused our attention on a region of the extracellular portion of VanSSC which may provide an interaction site with ligands like vancomycin. Given that the extracellular “sensor” domain shown in Fig. 1 is the most exposed and accessible region for ligand binding, a synthetic peptide containing VanSSC residues D38-F62, predicted to lie between TMD 1 and 2 and thus comprise the extracellular loop, was synthesised and purified. Topology analysis of the VanSSC sequence to yield the sequence of the extracellular region, here termed “sensor peptide”, is detailed in Methods. The membrane mimetic used in NMR studies was 100 mM DPC-d38/10 mM DPPC-d75 mixed micelles (or bicelles), as it has been reported that addition of 1,2-dipalmitoyl-sn-glycero-3-phosphocholine (DPPC) to detergents improves the quality of NMR data while providing a more native-like membrane environment, without a loss in signal-to-noise.

2-dimensional homonuclear NMR experiments, namely total correlation spectroscopy (TOCSY) and nuclear Overhauser enhancement spectroscopy (NOESY) experiments, were used to sequentially assign the sensor peptide in the presence of DPC-d38/DPPC-d75 mixed micelles (Figure S4, Table S1). Assignment was possible for all but three residues (P54, G55 and F58). Chemical shift index analysis of the 1Hα chemical shifts

Figure 3. (A) The coupled ADP-release assay used to assess constitutive autophosphorylation activity of His6-VanSSC. Following autophosphorylation, released ADP is regenerated to ATP by pyruvate kinase, and phosphoenol pyruvate (PEP) is converted to pyruvate. Lactate dehydrogenase converts pyruvate to lactate, oxidising NADH to NAD+. The loss of NADH in the sample is measured as a reduction in absorbance at 340 nm, which can therefore be utilised as an indirect measure of ADP release by VanSSC. (B) Turnover of ADP by His6-VanSSC (13.7 μM) over the course of a 3-minute continuous photometric kinase activity assay. μmol ADP released is estimated from the change in absorbance of the solution at 340 nm, caused by the conversion of NADH to NAD+. The specific activity of His6-VanSSC in 1.15 mM LMPG was estimated to be 6.9 μmol ADP released per mg kinase per minute. The activity of His6-VanSA was also assayed as a positive control (34.1 μM; see Supplementary Information), and estimated to be 4.6 μmol ADP released per mg kinase per minute.
for each residue indicates that the peptide is at least 72% α-helical (Fig. 5A). Long-range backbone (i, i+n) Hα, Hβ NOEs indicative of α-helix formation were detected in the presence of mixed micelles (Fig. 5A) and suggested a continuous helical stretch between residues G40-A52. A molecular model of this region is shown in Fig. 5A, with basic Arg residues shown in blue and hydrophobic residues shown in grey. The arrangement of these residues on discrete helical faces is similar to that observed in cationic amphipathic helices (APHs), known to have a natural affinity for bacterial membranes. To our knowledge, this is the first report of any regular structure for the sensor region of any VanS protein.

In the presence of a 1:1 molar ratio of vancomycin HCl, a considerable loss of crosspeak intensity was observed for protons in the sensor peptide in both the TOCSY and NOESY experiments (Fig. 5B). This attenuation of peaks precluded use of chemical shift to probe binding interactions, as severe broadening reduced the ability to measure chemical shift accurately. However, loss of crosspeak intensity itself can be indicative of ligand binding, with increased linewidths resulting from changes in dynamics or chemical shift averaging for nuclei in the binding site. With this in mind, TOCSY data were used to compare the relative loss of crosspeak intensity along the length of the sensor peptide. NOESY data were excluded from analyses since interpretation of NOESY crosspeak intensity is complicated by changes in internuclear distance, cross-relaxation and exchange rates in the free and bound species.

Figure 5B shows the significant attenuation of crosspeaks resulting from scalar coupling of the backbone amide and alpha protons (NH-Hα) in TOCSY spectra collected in the absence (blue) and presence (orange) of vancomycin using identical acquisition and processing parameters. All but two residues (D38 and Q39) that yielded observable crosspeaks in this region experienced severe attenuation in crosspeak volume upon addition of vancomycin. Such widespread broadening of peaks could be an indication of protein aggregation, leading to increased
broadening and eventual disappearance of all peaks. However, no visible change in the samples was observed (e.g., precipitation or cloudiness) and attenuation was much less pronounced in other regions of the NMR spectrum (Figure S5). For example, cross peaks in the aromatic and aliphatic regions of the spectrum were retained and did not show any pronounced change in chemical shift (as would be expected from large-scale aggregation events).

To investigate whether vancomycin could have this same effect on any highly helical peptide on the surface of a membrane, we acquired an equivalent dataset from a sample of vancomycin and the model amphipathic helix composed of residues 2–23 of human α-synuclein in DPC-d38/DPPC-d75 mixed micelles. We have previously demonstrated this peptide is highly helical in bicelles and detergent micelles. Here we observed no chemical shift change or attenuation of α-synuclein TOCSY crosspeaks (Figure S6) upon addition of an equimolar concentration of vancomycin, indicating that the signal intensity loss observed upon addition of vancomycin is selective for the VanSSC sensor peptide.

Vancomycin binds to VanSSC sensor-loop peptide via a region distinct from the Lipid II D-Alanyl-D-Alanine binding site. An orthogonal ligand-directed approach was also taken to monitor the nuclei within vancomycin under the same experimental conditions in order to locate the VanSSC-binding site within vancomycin. To our knowledge, no molecular model of this interaction site within the antibiotic has been proposed before, nor is it known whether this site maps to the Lipid II-binding site or is separate from that site. Therefore, we wished to reveal a molecular description of this binding site with atomic resolution using solution-state NMR spectroscopy.

Using 1H-1H TOCSY and 1H-1H NOESY spectra, the 1H resonances of vancomycin were assigned in three separate conditions: aqueous buffer; mixed micelles; and sensor peptide solubilised in mixed micelles. In 25 mM sodium phosphate buffer, pH 6.8, 96% of the assignable 1Hs in vancomycin were readily identified and the assignments were consistent with published values for vancomycin in CD3COOD-NaOD-D2O, pD 5.5 at 318 K.

Figure 5. (A) Survey of NMR-derived sequential backbone NOE connectivities for the VanSSC sensor peptide (D38–F62) solubilised in DPC-d38/DPPC-d75 mixed micelles (25 mM sodium phosphate, pH 6.8), classified as strong, weak, or absent by the thickness (or absence) of a bar connecting the residues involved. The non-sequential connectivities listed (i.e., i, i+n) are unique to α-helices, and were used alongside chemical shift index analyses (CSI) to localise α-helical stretches yielding a CSI of -1. Also shown is a molecular model of the continuous helical stretch from G40–A52, with basic residues coloured blue and hydrophobic residues coloured orange, indicating an amphipathic nature to the α-helix. (B) The assigned Hn - Hα fingerprint region of equivalent TOCSY spectra acquired for 1 mM sensor peptide in DPC/DPPC mixed micelles in the absence (blue) and presence (orange) of 1 mM vancomycin HCl. The Hn - Hα crosspeaks of some residues (e.g., Q25) are unaffected, while those of others (e.g., T44) are fully attenuated.
in (CD$_3$)$_2$SO, pD 6.0 at 298 K (Figure S7). Vancomycin was then re-assigned in mixed micelles in the absence (Table S2, Figure S8) and presence of a 1:1 molar ratio of sensor peptide, and the chemical shift changes are shown in Fig. 6A. We note that these chemical shift changes are small, but readily observable in the data (Fig. 6A, insets). A chemical shift change ($\Delta\delta$) equal to 0.04 ppm represents three standard errors above the average. Protons that experienced significant chemical shift changes in the presence of the sensor peptide are mapped as a heat map onto the vancomycin structure in Fig. 6B. Inspection of Fig. 6B revealed a discrete cluster of protons within or near the Leu residue at the N-terminus of the peptide component of vancomycin which were selectively impacted by the presence of the sensor peptide. We suggest that this region of vancomycin is involved in binding to the sensor peptide. To confirm the specificity of this interaction, the experiment was repeated using the membrane-bound amphipathic helix, $\alpha$-synuclein, as a negative control in place of the VanSSC sensor loop. In this case, very few vancomycin protons experienced chemical shift perturbation (see Figure S9), and these protons do not cluster together to form a recognisable binding site. Also shown in Fig. 6B are the hydrogen and oxygen atoms which form the d-Alanyl-d-Alanine binding site upon binding of vancomycin to Lipid II (39). These atoms are indicated by dotted spherical cage representations.

Figure 6. (A) The change in chemical shift ($\Delta\delta$) of each proton in vancomycin HCl upon addition of an equimolar quantity of the VanSSC sensor loop peptide. Asterisks indicate protons for which no $\Delta\delta$ is observed. Insets show overlaid spectra before (black) and after (red) addition of sensor peptide to highlight resolution of peaks that shift by $\geq 0.04$ ppm $\Delta\delta$. (B) The crystal structure of vancomycin (PDB ID: 1FVM, crystallised in complex with the lipid II pentapeptide terminus) onto which protons observable in acquired NMR spectra are mapped as solid spheres. The signal perturbations experienced by all observable protons in the presence of the sensor peptide are shown as a heat map on the structure above, with protons experiencing the largest signal perturbation ($\Delta\delta \geq 0.04$ ppm, $3 \times$ standard error) shown in dark cyan, and then varying in shade between $\Delta\delta = 0.04$–0.02 ppm. Protons experiencing $\Delta\delta$ from 0–0.2 ppm are shown in red to represent negligible perturbation. Atoms involved in hydrogen bonding to lipid II are indicated by dotted spherical cage representations.
Several protons that lie outside of the putative sensor peptide “binding site” also respond to the addition of the sensor peptide. Vancomycin is known to form both dimers and higher-order oligomers in some circumstances and specifically, has been reported to form dimers at concentrations above 1.4 mM. Although vancomycin was added here at a concentration below 1.4 mM (i.e. 1 mM), we cannot rule out the formation of vancomycin dimers under these conditions. The vancomycin protons that experience significant chemical shift changes and lie at the dimer interface in the vancomycin dimer structure (PDB ID: 1AA5) are shown in Figure S10 (denoted by spherical cages). One of these protons (N5, see Figure S8) yielded the largest chemical shift change observed in this study.

Discussion

VanS is a large, homodimeric integral membrane protein. As such, structural characterisation of VanS is highly challenging. While recent studies have demonstrated production of highly pure and active samples of A-type VanS, which have been characterised using techniques including circular dichroism and analytical ultracentrifugation, characterisation via high-resolution methods such as X-ray crystallography and NMR spectroscopy has met with very little success. Thus far, structural understanding of VanS has been gleaned from comparison to other sensor histidine kinases of known structure. However, while the transmembrane and cytosolic components of sensor histidine kinases show significant homology, this class of protein is known to respond to a wide variety of stimuli, and this is reflected in the variety of solved structures of sensor histidine kinase extracellular domains in the literature. This lack of structural characterisation of the VanS extracellular domain has hampered our understanding of the architecture of this protein and any ability to target VanS therapeutically. Here we describe characterisation of the secondary structure content and oligomeric state of a purified and active B-type VanS from S. coelicolor, VanSSC. We show that the predominant oligomeric state of the protein is that of a dimer, reflecting the assembly of this protein in vivo. The secondary structure content of this form of VanSSC is sufficient to include those of other histidine kinase family members. The dimeric form of purified VanSSC observed in ligand-free protein preparations is in contrast to the predominantly monomeric form of the related A-type VanS observed in the absence of ligand by Phillips-Jones and co-workers. This difference may be due to differences in the solution conditions used; VanS oligomerisation was measured here in detergent micelles and was measured previously in a detergent-free solution supplemented with 20% glycerol.

Our results agree well, however, with the results for A-type VanS mentioned above in that our data demonstrate direct vancomycin-VanSSC interactions in vitro using a purified and active VanSSC sample. Previously a highly functionalised vancomycin analogue was proposed to interact directly with VanSSC, Koteva et al. reported binding of VanSSC to a vancomycin photoaffinity probe in E. coli membrane fractions. The work we present here is unique in that binding has been demonstrated in a purified sample of VanSSC with chemically unchanged vancomycin, supporting the hypothesis that a direct interaction between vancomycin and VanS is a means of signalling in the antibiotic resistance mechanism. We note that the link between vancomycin binding and VanS activity is still the subject of much debate, with separate recent studies of the A-type VanS from E. faecium reporting that enzyme activity is both sensitive and insensitive to vancomycin in vitro.

The sensor peptide used in this work, derived from the extracellular region of VanSSC, readily folds into a highly α-helical structure in the presence of membrane mimetics. This is the first report, to our knowledge, of any higher order structure in this region of VanSSC. Given that this extracellular region, anchored by flanking transmembrane domains, must always be in close proximity to a membrane surface we suggest that the high propensity for helical structure we observe here may represent the native fold. High helical propensities in the extra- cellular loops of other integral membrane proteins including G-protein-coupled receptors, transporters, Na/Ca exchangers, tetraspanins, and the cell division protein FtsX have been reported previously. The presence of these helical elements is often thought to direct specific interactions with binding partners. For example, in the case of Fe(III)-phytosiderophore transporters, the helical propensity of the seventh extracellular loop is thought to control substrate specificity. Likewise, the second extracellular loop of the tetraspanin human occludin has been shown to adopt a helical fold, and the authors link this fold to the unique ability of this region to interact with other endothelial tight junction proteins. These and other studies give weight to the argument that the helical structure we observe in the VanSSC extracellular loop is not an artefact, but instead reflects formation of a structured binding site for vancomycin (and possibly other antibiotics). We also note that the arrangement of basic Arg residues and strongly hydrophobic residues on discrete helical faces in this region of VanSSC is similar to that observed in cationic APHs, known to have a natural affinity for bacterial membranes which are enriched in anionic lipids. Such an interaction is commonly observed for antimicrobial peptides, which use their cationic nature to selectively target and lyse bacterial membranes. It is plausible that an interaction with the bacterial membrane could facilitate the prearrangement of a binding site; indeed, this has been shown recently for a bacterial glycosyltransferase which utilises cationic helix-bacterial membrane interactions to direct productive binding between the jaw domain and Lipid II. Thorough analysis of peak volumes in all TOCSY spectra revealed that significant broadening of main chain H NMR signals occurred along almost the entire length of the sensor region upon addition of a 1:1 molar ratio of vancomycin, precluding identification of an isolated binding site in the protein, but strongly suggestive of a large-scale change in mobility. Taken together, our data indicate binding of the antibiotic vancomycin to a highly helical VanSSC extracellular domain.

We have mapped the VanSSC sensor domain-binding site in vancomycin to the N-terminal leucine of the polypeptide chain within the antibiotic, and find that the VanS binding site is distinct from the D-alanyl-D-alanine binding site on Lipid II. Such a distinction may provide a system for detection of vancomycin in both Lipid II-bound and unbound states; thus, for VanSSC, to target a distinct binding site not obscured by vancomycin-lipid II binding is evolutionarily advantageous. It is worth noting that deletion of this N-terminal leucine in vancomycin inhibits antibiotic activity, so VanSSC binding cannot easily be evaded by mutation of the sidechain. However, a predictable consequence of this separate binding site is the emergence of modified glycopeptides to

Ca exchangers, tetraspanins, and the cell division protein FtsX have been reported previously. The presence of stimuli, and this is reflected in the variety of solved structures of sensor histidine kinase extracellular domains in the literature. This lack of structural characterisation of the VanS extracellular domain has hampered our understanding of the architecture of this protein and any ability to target VanS therapeutically. Here we describe characterisation of the secondary structure content and oligomeric state of a purified and active B-type VanS from S. coelicolor, VanSSC. We show that the predominant oligomeric state of the protein is that of a dimer, reflecting the assembly of this protein in vivo. The secondary structure content of this form of VanSSC is sufficient to include those of other histidine kinase family members. The dimeric form of purified VanSSC observed in ligand-free protein preparations is in contrast to the predominantly monomeric form of the related A-type VanS observed in the absence of ligand by Phillips-Jones and co-workers. This difference may be due to differences in the solution conditions used; VanS oligomerisation was measured here in detergent micelles and was measured previously in a detergent-free solution supplemented with 20% glycerol.

Our results agree well, however, with the results for A-type VanS mentioned above in that our data demonstrate direct vancomycin-VanSSC interactions in vitro using a purified and active VanSSC sample. Previously a highly functionalised vancomycin analogue was proposed to interact directly with VanSSC, Koteva et al. reported binding of VanSSC to a vancomycin photoaffinity probe in E. coli membrane fractions. The work we present here is unique in that binding has been demonstrated in a purified sample of VanSSC with chemically unchanged vancomycin, supporting the hypothesis that a direct interaction between vancomycin and VanS is a means of signalling in the antibiotic resistance mechanism. We note that the link between vancomycin binding and VanS activity is still the subject of much debate, with separate recent studies of the A-type VanS from E. faecium reporting that enzyme activity is both sensitive and insensitive to vancomycin in vitro.

The sensor peptide used in this work, derived from the extracellular region of VanSSC, readily folds into a highly α-helical structure in the presence of membrane mimetics. This is the first report, to our knowledge, of any higher order structure in this region of VanSSC. Given that this extracellular region, anchored by flanking transmembrane domains, must always be in close proximity to a membrane surface we suggest that the high propensity for helical structure we observe here may represent the native fold. High helical propensities in the extracellular loops of other integral membrane proteins including G-protein-coupled receptors, transporters, Na/Ca exchangers, tetraspanins, and the cell division protein FtsX have been reported previously. The presence of these helical elements is often thought to direct specific interactions with binding partners. For example, in the case of Fe(III)-phytosiderophore transporters, the helical propensity of the seventh extracellular loop is thought to control substrate specificity. Likewise, the second extracellular loop of the tetraspanin human occludin has been shown to adopt a helical fold, and the authors link this fold to the unique ability of this region to interact with other endothelial tight junction proteins. These and other studies give weight to the argument that the helical structure we observe in the VanSSC extracellular loop is not an artefact, but instead reflects formation of a structured binding site for vancomycin (and possibly other antibiotics). We also note that the arrangement of basic Arg residues and strongly hydrophobic residues on discrete helical faces in this region of VanSSC is similar to that observed in cationic APHs, known to have a natural affinity for bacterial membranes which are enriched in anionic lipids. Such an interaction is commonly observed for antimicrobial peptides, which use their cationic nature to selectively target and lyse bacterial membranes. It is plausible that an interaction with the bacterial membrane could facilitate the prearrangement of a binding site; indeed, this has been shown recently for a bacterial glycosyltransferase which utilises cationic helix-bacterial membrane interactions to direct productive binding between the jaw domain and Lipid II. Thorough analysis of peak volumes in all TOCSY spectra revealed that significant broadening of main chain H NMR signals occurred along almost the entire length of the sensor region upon addition of a 1:1 molar ratio of vancomycin, precluding identification of an isolated binding site in the protein, but strongly suggestive of a large-scale change in mobility. Taken together, our data indicate binding of the antibiotic vancomycin to a highly helical VanSSC extracellular domain.

We have mapped the VanSSC sensor domain-binding site in vancomycin to the N-terminal leucine of the polypeptide chain within the antibiotic, and find that the VanS binding site is distinct from the D-alanyl-D-alanine binding site on Lipid II. Such a distinction may provide a system for detection of vancomycin in both Lipid II-bound and unbound states; thus, for VanSSC, to target a distinct binding site not obscured by vancomycin-lipid II binding is evolutionarily advantageous. It is worth noting that deletion of this N-terminal leucine in vancomycin inhibits antibiotic activity, so VanSSC binding cannot easily be evaded by mutation of the sidechain. However, a predictable consequence of this separate binding site is the emergence of modified glycopeptides to
which VanSSc cannot bind, but which are capable of binding to lipid II. Indeed, this has already been reported. To our knowledge, a secondary protein-binding site on any glycopeptide antibiotic has not been reported until now. This understanding could guide design and screening of therapeutic molecules that block activation of the two-component system. Our data also support a model in which sensor-peptide binding may stimulate vancomycin dimerisation. Such behaviour would facilitate binding to the sensor region of an adjacent VanSSc chain (which would be present in the VanSSc dimer). Dimerisation of glycopeptide antibiotics has previously been suggested to offer a binding advantage over monomers in solution, facilitating interactions between antibiotics and their binding targets by inducing accumulation of the antibiotic at the membrane surface.

Methods

Heterologous overexpression and purification of full-length His6-VanSSc. The sequence encoding the S. coelicolor VanS histidine kinase (UniProt ID Q9X942_STRCO) was codon optimised for E. coli and cloned into the pProEX vector containing an N-terminal hexahistidine tag to create the pProEx::His6-VanSSc plasmid. E. coli C41 (DE3) pRIL transformed with pProEx::His6-VanSSc was cultured at 37 °C, 180 rpm, in Luria-Burtani medium containing 35 μg/mL chloramphenicol and 100 μg/mL carbenicillin. At OD600 = 0.6, expression of VanSSc was induced by the addition of 200 μM isopropyl-β-d-thiogalactoside (IPTG). Cultures were then incubated at 25 °C, 180 rpm, overnight and cells were harvested by centrifugation at 3,000 × g at 4 °C for 30 minutes. Cells were homogenised in 25 mM sodium phosphate buffer at pH 6.8, containing 25 mM NaCl and 10% glycerol, by two passes through a Constant Systems cell disruptor at 25 kpsi, 4 °C. Cell debris was removed by lysates by centrifugation at 20,000 × g at 4 °C for 30 minutes. Membranes were then pelleted by centrifugation at 200,000 × g for 2 hours at 4 °C, and resuspended in binding buffer (25 mM sodium phosphate buffer at pH 6.8, containing 25 mM NaCl and 10 mM dodecylphosphocholine (DPC) or 6.7 mM 1-myristoyl-2-hydroxy-sn-glycero-3-phospho-(1'-rac-glycerol) (LMPG) (Avanti Polar Lipids, Alabaster, USA). Purification was achieved using immobilised metal affinity chromatography (IMAC) by cycling clarified, detergent-solubilised membranes through a 5 mL prepacked HisTrap HP column (GE Life sciences, USA) at a rate of 1 mL/min for 2 hours at 4 °C, followed by washing of the column in binding buffer, binding buffer with 1 M NaCl, and binding buffer with 50 mM imidazole, and subsequent eluting of His6-VanSSc in binding buffer with 300 mM imidazole. The purity of all protein fractions at each stage of preparation was assessed using sodium dodecyl sulphate polycrylamide gel electrophoresis (SDS-PAGE, visualised using both Coomassie Blue R250 and silver nitrate) and immunoblotting against the His6 tag.

Analytical gel filtration chromatography. Oligomerisation of full-length VanSSc solubilised in DPC detergent micelles was analysed using analytical gel filtration chromatography on a 10/300 mm Superose 12 column (GE Healthcare) attached to an AKTA Prime system (GE Healthcare). Equilibration of the column was performed with Buffer A (Buffer A: 20 mM HEPES, pH 7.8, 200 mM NaCl, and 0.075% DPC) before protein samples were loaded. Separation was accomplished at a flow rate of 0.3 mL/min under isocratic conditions until a volume corresponding to 1.5 column bed volumes (36 mL) was collected in 0.3 ml fractions. Protein absorbance was recorded at 280 nm and 254 nm wavelengths, and the elution volume (Ve) of VanS Sc was determined and compared to those obtained for a set of protein standards (GE Healthcare) under identical conditions to yield an estimation of molecular weight. The standards used were as follows: aprotinin (Apro, 6.5 kDa); ribonuclease A (‘Ribo’, 13.7 kDa); carbonic anhydrase (‘CA’, 29 kDa); bovine serum albumin (‘BSA’, 66.9 kDa); and aldolase (‘Aldo’, 158 kDa).

Blue native-PAGE. Oligomerisation of full-length VanSSc solubilised in DPC detergent micelles was also analysed using the NativePAGE Novex Bis-Tris system (Invitrogen), based on the BN-PAGE technique. Proteins were separated on a 4–16% Bis-Tris gradient gel at 4 °C in NativePAGE running buffer (1 M Bis-Tris−HCl pH 7.0, 1 M Tricine pH 7.0). Samples were prepared in a non-denaturing Coomassie G-250 dye, which confers a net negative charge while maintaining the proteins in their non-denatured native state. Proteins were visualised using Coomassie Brilliant Blue and molecular weights were estimated relative to prestained markers (High MW Standards, Amersham).

Autophosphorylation activity assay. The native activity of full length VanSSc was measured by a coupled enzymatic activity assay. 13.7 μM His6−VanSSc was incubated at room temperature with 1 mM ATP, 6 units PK, 2 mM PEP, 8.4 units LDH, and 100 μM NADH, in the presence of 50 mM KCl and 1 mM DTT in 25 mM sodium phosphate buffer pH 6.8, 25 mM NaCl, 1.15 mM LMPG. The phosphorylation assay could not be performed in DPC; presumably monomeric DPC, present at 1–1.5 mM concentrations due to its relatively high CMC, adversely affects the activity of one of the enzymes in the assay.

Fluorescence spectroscopy. The interaction between vancomycin and full-length VanSSc was initially measured by fluorescence spectroscopy. A 10 μM solution of fluorescently labelled vancomycin probe, BODIPY-vancomycin (Molecular Probes, Sigma-Aldrich), in 20 mM HEPES buffer pH 7.8, was excited at 504 nm on a Perkin Elmer LS50 fluorometer with slit width 1 nm and scan speed 50 nm/min at 20 degrees, and its emission spectrum monitored from 500 to 600 nm. To investigate the impact of micelles on BODIPY-vancomycin fluorescence, equivalent spectra were recorded from the sample following addition of DPC to a concentration of 1 mM and 2 mM. Subsequently, to investigate the impact of a known vancomycin ligand on fluorescence, spectra were recorded following addition of Lipid II to the sample of BODIPY-vancomycin and 2 mM DPC, to concentrations of 10, 20, 30, and finally 40 μM. A stock solution of 660 μM Lipid II was prepared in 2:3:1 chloroform:methanol:water, and aliquots of this stock were dried under nitrogen. Successive Lipid II films were then solubilised in a sample of BODIPY-vancomycin, DPC and HEPES buffer, to yield mixed BODIPY-vancomycin/
Lipid II samples for the investigation. Finally, to investigate binding between vancomycin and VanSSC, samples of BODIPY-vancomycin, 2 mM DPC, and 1, 2, 3 and 4 μM VanSSC were generated and emission spectra recorded.

**Peptide synthesis and purification.** The transmembrane domains of VanSSC were predicted via analysis of the sequence of the VanS histidine kinase from *S. coelicolor* (UniProt ID Q9X942_STRCO) using Phoibus. A 25-residue peptide corresponding to the extracellular loop in VanSSC (residues 38–62), with the sequence DQGWLLTNERGAVRATPGTVFLRSF, was synthesised using F-moc chemistry and purified to 95% purity at Insight Biotechnology Limited (Wembley, UK). Similarly, a peptide containing residues 2–23 of human α-synuclein, with the sequence DVPMKGLSKEGVVAAEKT, was also synthesised. Peptide purity was confirmed by HPLC and matrix-assisted time of flight mass spectrometry (MALDI-TOF-MS, Bruker) before subsequent lyophilisation. The peptide was stored as dry powder at −20 °C until use.

**Circular dichroism spectroscopy.** CD spectra were collected on Jasco J-815 or J-720 spectropolarimeters (Jasco UK, Great Dunmow, UK) equipped with Peltier temperature control and xenon light sources. VanSSC samples contained 0.42 mg/mL (10 μM) protein, 2 mM DPC or 1.15 mM LMPG, 25 mM sodium phosphate (pH 6.8), and 25 mM NaCl. Peptide samples contained 0.5 mg/mL (100 μM) VanSSC sensor peptide, 100 mM DPC or LMPG, 25 mM sodium phosphate (pH 6.8), and 25 mM NaCl. Spectra were recorded between 190 nm and 280 nm, with a bandwidth of 2 nm and a data pitch of 0.2 nm. The CD spectrum of the buffer was recorded as a blank and was subtracted from each protein spectrum. The percentage of secondary structure content was estimated from mean residue ellipticity at 222 nm.

**NMR experiments.** All NMR experiments were performed in 3 mm NMR tubes (Bruker, Germany) on an Avance 700 MHz spectrometer (Bruker Biospin, UK) equipped with a triple resonance inverse cryoprobe with Z-gradients. Data were processed using Topspin 3.0 (Bruker Biospin), and analysed using Topspin 3.0 and CcpNmr Analysis (University of Leicester, UK).

Peptide samples for NMR analyses were prepared by dissolving the peptide to a final concentration of 0.8–1 mM in 25 mM Na3HPO4 (pH 6.8), 90% H2O, 10% D2O, containing 100 mM DPC-d38 and 10 mM DPPC-d75 with Z-gradients. Data were processed using Topspin 3.0 (Bruker Biospin), equipped with a triple resonance inverse cryoprobe with Z-gradients. 1H-1H TOCSY and NOESY NMR spectra were recorded with 4096 × 256 data points or 4096 × 512 data points at a temperature of 25 °C. TOCSY and NOESY mixing times ranged from 70–140 ms and 80–180 ms, respectively. Chemical shift indices for peptide α-protons were calculated using random coil reference values. Percent attenuation of peptide crosspeak volumes collected for samples containing no vancomycin (Vfree) or a 1:1 molar ratio of vancomycin:peptide (VBd) were calculated according to the following equation: % Attenuation = (Vfree - Vvd)/Vfree × 100.

Received: 9 December 2019; Accepted: 11 March 2020; Published online: 31 March 2020

**References**

1. Sharma, R. & Hammerschlag, M. R. Treatment of Methicillin-Resistant Staphylococcus aureus (MRSA) Infections in Children: a Reappraisal of Vancomycin. *Curr. Infect. Dis. Rep.* 21, 37 (2019).

2. Antimicrobial Resistance: Biggest Threats and Data, https://www.cdc.gov/drugresistance/biggest_threats.html (2017).

3. Tillotson, G. A crucial list of pathogens.

4. Weigel, L. M. et al. Antibiotic Resistance Is Ancient. *Nature* 447, 457–461 (2011).

5. Weigel, L. M. et al. Genetic Analysis of a High-Level Vancomycin-Resistant Isolate of Staphylococcus aureus. *Science* 302, 1569–1571 (2003).

6. Bugg, T. D. H. et al. Molecular Basis for Vancomycin Resistance in Enterococcus faecium BM4147: Biosynthesis of a Dipeptidase Peptidoglycan Precursor by Vancomycin Resistance Proteins VanH and VanA. *Biochemistry* 30, 10408–10415 (1991).

7. Arthur, M. & Courvalin, P. Genetics and Mechanisms of Glycopeptide Resistance in Enterococci. *Antimicrob. Agents Chemother.* 37, 1563–1571 (1993).

8. Arthur, M. & Courvalin, P. Vancomycin Resistance in Gram-Positive Coci. *Clin. Infect. Dis.* 42, S25–S34 (2006).

9. Reynolds, P. E., Depardieu, F., Dutka-Malen, S., Arthur, M. & Courvalin, P. Glycopeptide Resistance Mediated by Enterococcal Transposon Tn1546 and Related Elements in the Absence of Induction. *J. Bacteriol.* 179, 1065–1070 (1997).

10. Arthur, M. & Courvalin, P. Transposon Tn 1546 Requires Production of VanX for Hydrolysis of D-Alanyl-D-Alanine. *Mol. Microbiol.* 29, 2379–2386 (1998).

11. Arthur, M. & Courvalin, P. Vancomycin Resistance in Enterococcus faecium BM4147: Biosynthesis of a Dipeptidase Peptidoglycan Precursor by Vancomycin Resistance Proteins VanH and VanA. *Biochemistry* 30, 10408–10415 (1991).

12. Wright, G. D. et al. The VanS Sensor Negatively Controls VanR-Mediated Transcriptional Activation of Glycopeptide Resistance Genes of Tn1546 and Related Elements in the Absence of Induction. *J. Bacteriol.* 179, 97–106 (1997).

13. Arthur, M. et al. The VanS Sensor Negatively Controls VanR-Mediated Transcriptional Activation of Glycopeptide Resistance Genes of Tn1546 and Related Elements in the Absence of Induction. *J. Bacteriol.* 179, 97–106 (1997).

14. Arthur, M. et al. The VanS Sensor Negatively Controls VanR-Mediated Transcriptional Activation of Glycopeptide Resistance Genes of Tn1546 and Related Elements in the Absence of Induction. *J. Bacteriol.* 179, 97–106 (1997).

15. Arthur, M. et al. The VanS Sensor Negatively Controls VanR-Mediated Transcriptional Activation of Glycopeptide Resistance Genes of Tn1546 and Related Elements in the Absence of Induction. *J. Bacteriol.* 179, 97–106 (1997).
21. Hulko, M. et al. The HAMP Domain Structure Implies Helix Rotation in Transmembrane Signaling. Cell 126, 929–940 (2006).
22. Koteva, K. et al. A Vancomycin Photoprobe Identifies the Histidine Kinase VanSSC as a Vancomycin Receptor. Nat. Chem. Biol. 6, 327–329 (2010).
23. Hughes, C. S., Longo, E., Phillips-Jones, M. K. & Hussain, R. Characterisation of the Selective Binding of Antibiotics Vancomycin and Teicoplanin by the VanS Receptor Regulating type A Vancomycin Resistance in the Enterococci. Biochim. Biophys. Acta 1861, 1951–1959 (2017).
24. Baptista, M., Depardieu, F. & Courvalin, P. Specificity of Induction of Glycopeptide Resistance Genes in Enterococcus faecalis. Antimicrob. Agents Chemother. 40, 2291–2295 (1996).
25. Kwon, M. J., Novotna, G., Hesketh, A. R., Hill, L. & Hong, H.-J. In vivo Studies Suggest that Induction of VanS-Dependent Vancomycin Resistance Requires Binding of the Drug to D-Ala-D-Ala Termini in the Peptidoglycan Cell Wall. Antimicrob. Agents Chemother. 57, 4470–4480 (2013).
26. Schibli, D. J., Montelaro, R. C. & Vogel, H. J. The Membrane-Proximal Tryptophan-Rich Region of the HIV Glycoprotein, gp41, Forms a Well-Defined Helix in Dodecylphosphocholine Micelles. Biochemistry 40, 9570–9578 (2001).
27. Kang, C. et al. Structure of KCNE1 and Implications for How it Modulates the KCNQ1 Potassium Channel. Biochemistry 47, 7999–8006 (2008).
28. Maslennikov, I. et al. Membrane Domain Structures of Three Classes of Histidine Kinase Receptors by Cell-Free Expression and Rapid NMR Analysis. Proc. Natl. Acad. Sci. USA 107, 10902–10907 (2010).
29. Klammt, C. et al. Facile Backbone Structure Determination of Human Membrane Proteins by NMR Spectroscopy. Nat. Methods 9, 834–839 (2012).
30. Ysselstein, D. et al. Effects of Impaired Membrane Interactions on α-Synuclein Aggregation and Neurotoxicity. Neurobiol. Dis. 79, 150–163 (2015).
31. Milburn, D., Laskowski, R. A. & Thornton, J. M. Sequences Annotated by Structure: a Tool to Facilitate the Use of Structural Information in Sequence Analysis. Protein Eng. 11, 855–859 (1998).
32. Szurmunt, H., White, R. A. & Hoch, J. A. Sensor Complexes Regulating Two-Component Signal Transduction. Curr. Opin. Struct. Biol. 17, 706–715 (2007).
33. Schagger, H., Cramer, W. A. & von Jagow, G. Analysis of Molecular Masses and Oligomeric States of Protein Complexes by Blue Native Electrophoresis and Isolation of Membrane Protein Complexes by Two-Dimensional Native Electrophoresis. Anal. Biochem. 217, 220–230 (1994).
34. Potter, C. A. et al. Expression, Purification and Characterisation of Full-Length Heterologously Expressed Histidine Kinase Protein RegB from Rhodobacter sphaeroides. J. Mol. Biol. 320, 201–213 (2002).
35. Wampler, D. E. & Westhead, E. W. Two Aspartokinases from Escherichia coli. Nature of the Inhibition and Molecular Changes Accompanying Reversible Inactivation. Biochemistry 7, 1661–1671 (1968).
36. Vidal, A., Alldred, D. C. & Hendrickson, W. A. Structure of the Entire Cytoplasmic Portion of a Sensor Histidine-kinase Protein. EMBO J. 34, 4247–4259 (2005).
37. Warschawski, D. E. et al. Choosing Membrane Mimetics for NMR Structural Studies of Transmembrane Proteins. BBA. Biomembranes 1808, 1957–1974 (2011).
38. Yang, T. W., Sheiko, K. J. & Loll, P. J. Vancomycin does not affect the enzymatic activities of purified VanSA. PlaSS ONE 14, e0210627 (2019).
39. Barna, J. C. & Williams, D. H. The Structure and Mode of Action of Glycopeptide Antibiotics of the Vancomycin Group. Ann. Rev. Microbiol. 38, 339–357 (1984).
40. Walsh, C. T., Fisher, S. L., Park, I. S., Prahalad, M. & Wu, Z. Bacterial Resistance to Vancomycin: Five Genes and one Missing Hydrogen Bond Tell the Story. Chem. Biol. 3, 21–28 (1996).
41. Ortega-Roldan, J. L., Ossa, F., Amin, N. T. & Schnell, J. R. Solution NMR Studies Reveal the Location of the Second Transmembrane Domain of the Human Sigma-1 Receptor. FEBS Lett. 589, 659–665 (2015).
42. Bax, A. & Davies, D. G. MLEV-17-Based Two-Dimensional Homonuclear Magnetization Transfer Spectroscopy. J. Magn. Reson. 65, 355–360 (1985).
43. Hwang, T. L. & Shaka, A. J. Water Suppression That Works. Excitation Sculpting Using Arbitrary Waveforms and Pulsed-Field Gradients. J. Magn. Reson. Ser. A 112, 275–279 (1995).
44. Wüthrich, K. NMR of Proteins and Nucleic Acids. (Wiley, 1991).
45. Wishart, D. S., Sykes, B. D. & Richards, F. M. The Chemical Shift Index: a Fast and Simple Method for the Assignment of Protein Structures. J. Magn. Reson. Ser. A 110, 329–340 (1993).
46. Misra, R. L. & Dixon, A. Revealing the mechanism of protein-lipid interactions for a putative membrane curvature sensor in plant endoplasmic reticulum. BBA Biomed Membranes 1862, doi:10.1016/j.bbamem.2019.183160 (2020).
47. Convert, O., Bongini, A. & Feeney, J. A 1H Nuclear Magnetic Resonance Study of the Interactions of Vancomycin with N-Acetyl-D-Alanyl-D-Alanine and Related Peptides. J. Chem. Soc., Perkin Trans. 2(8), 1262–1270 (1980).
48. Moore, J. O. & Hendrickson, W. A. Structural Analysis of Sensor Domains from the TMAO-Responsive Histidine Kinase Receptor TorS. Structure 17, 1195–1204 (2009).
49. Kim, T. et al. Structural Studies on the Extracellular Domain of Sensor Histidine Kinase YycG from Staphylococcus aureus and Its Functional Implications. J. Mol. Biol. 428, 3074–3089 (2016).
50. Rinaldi, J. et al. Structural Insights into the HWE Histidine Kinase Family: The Brucella Blue Light-Activated Histidine Kinase Domain. J. Mol. Biol. 428, 1165–1179 (2016).
51. Warne, T. et al. Structure of a β1-Adrenergic G-Protein-Coupled Receptor. Nature 454, 486–491 (2008).
52. Wheatley, M. et al. Lifting the Lid on GPCRs: the Role of Extracellular Loops. Br. J. Pharmacol. 165, 1688–1703 (2012).
53. Harada, E., Sugase, K., Namba, K. & Murata, Y. The Helical Propensity of the Extracellular Loop is Resistant for the Substrate Specificity of Fe(II)-Phytosiderophore Transporters. FEBS Lett. 590, 4617–4627 (2016).
62. Plain, F. et al. An Amphipathic Helix Directs Palmitoylation of the Large Intracellular Loop of the Sodium/Calcium Exchanger. J. Biol. Chem. 292, 10745–10752 (2017).
63. Nusrat, A. et al. Multiple Protein Interactions Involving Proposed Extracellular Loop Domains of the Tight Junction Protein Occludin. Mol. Biol. Cell 16, 1725–1734 (2005).
64. Rued, B. E. et al. Structure of the Large Extracellular Loop of FtsX and its Interaction with the Essential Peptidoglycan Hydrolase PcSb in Streptococcus pneumoniae. MBio 10, e02622–e02618 (2019).
65. Mahlapuu, M., Häkansson, J., Ringstad, L. & Björn, C. Antimicrobial Peptides: An Emerging Category of Therapeutic Agents. Front. Cell. Infect. Microbiol. 6, https://doi.org/10.3389/fcimb.2016.00194 (2016).
66. Punekar, A. S. et al. The Role of the Jaw Subdomain of Peptidoglycan Glycosyltransferases for Lipid II Polymerization. Cell. Surf. 2, 54–66 (2018).
67. Patti, G. J. et al. Vancomycin and Oritavancin have Different Modes of Action in Enterococcus faecium. J. Mol. Biol. 392, 1178–1191 (2009).
68. Beauregard, D. A., Williams, D. H., Gwynn, M. N. & Knowles, D. J. Dimerization and Membrane Anchors in Extracellular Targeting of Vancomycin Group Antibiotics. Antimicrob. Agents Chemother. 39, 781–785 (1995).

Acknowledgements
C. Lockey was supported by a studentship grant funded by the Engineering and Physical Sciences Research Council (grant EP/F500378/1) through the MOAC Doctoral Training Centre. R. Edwards was supported by studentship and capacity building grants funded by the Medical Research Council (grants G0900208-1/1 and G1000412/1, respectively). Lipid II was provided by Julie Tod and Anita Catherwood and was supported by MRC grants G0500643 and G0701400. The experimental data for this study are provided as a supporting data set from WRAP, the Warwick Research Archive Portal at http://wrap.warwick.ac.uk.

Author contributions
C.L., R.J.E., D.I.R. and A.M.D. Conceptualisation; C.L. and A.M.D. Data curation; C.L. and R.J.E. Formal analysis; A.M.D. and D.I.R. Funding acquisition; C.L. and R.J.E. Investigation; C.L., R.J.E., D.I.R. and A.M.D. Methodology; C.L., R.J.E., D.I.R. and A.M.D. Project administration; A.M.D. and D.I.R. Resources; A.M.D. and D.I.R. Supervision; C.L. and A.M.D. Validation; C.L. and A.M.D. Roles/Writing - original draft; C.L., D.I.R. and A.M.D. Writing - review & editing; C.L. and A.M.D. Preparation of all images, drawings and figures.

Competing interests
The authors declare no competing interests.

Additional information
Supplementary information is available for this paper at https://doi.org/10.1038/s41598-020-62557-z.
Correspondence and requests for materials should be addressed to A.M.D.

Reprints and permissions information is available at www.nature.com/reprints.

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2020